Fig. 2

Patient disposition. ^aIn Panel 2, one patient in the GT1b/without RBV group had <25 IU/mL detectable HCV RNA at Week 4 and, therefore, met the criterion for a 12-week follow-up treatment with pegIFN/RBV. This patient refused to receive follow-up treatment. ^bIn Panel 4, the results of the Trugene or LiPA test performed at screening were used to randomise the patients to the 30-mg or 60-mg dose of JNJ-56914845. For analyses purposes, NS5B sequencing was used to determine the HCV geno/subtype. Based on this method, the geno/subtype for two patients in the 30-mg group was found to be non-1a, non-1b (1c, n = 1; 1l, n = 1) based on geno/subtyping using NS5B sequencing. These two patients were analysed together with the GT1a-infected patients in the category ‘GT1a/other’. DAA direct-acting antiviral agent, FU follow-up, GT genotype, HCV hepatitis C virus, pegIFN pegylated interferon α-2a, RBV ribavirin